Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides

Cancer Gene Therapy

Volumn 7, Issue 7, 2000, Pages 997-1007

  Eder, Iris E ^a   Culig, Zoran ^a   Ramoner, Reinhold ^a   Thurnher, Martin ^a   Putz, Thomas ^a   Nessler Menardi, Claudia ^a   Tiefenthaler, Martin ^b   Bartsch, Georg ^a   Klocker, Helmut ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Androgen receptor; Antisense oligodeoxynucleotides; LNCaP; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0033930522     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700202     Document Type: Article

References (51)

1. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419-424.
2. Wilding G. Endocrine control of prostate cancer. Cancer Surv. 1995;23:43-62.
3. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 1990;50:3748-3753.
4. Ruizevelt de Winter JA, Janssen PJA, Sleddens HMEB, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994;144:735-746.
5. Van der Kvast TH, Schalken J, Ruizeveld de Winter JA, et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer. 1991;48:189-193.
6. Hobisch A, Culig A, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 1995;55: 3068-3072.
7. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Androgen receptor status of lymph node metastases from prostate cancer. Prostate. 1996;28:129-135.
8. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978;21:274-281.
9. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979;17:16-23.
10. Isaacs JT, Coffey DS. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res. 1981;41:5070-5075.
11. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9:401-406.
12. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997;57:314-319.
13. Kokontis J, Takamura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 1994;54:1566-1573.
14. Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer. 1999;81:242-251.
15. Klocker H, Culig Z, Hobisch A, et al. Androgen receptor structure and prostate cancer. In: In: Luciani L, Debruyne FMJ, Schalken JA, eds. Basic Research in Urological Oncology. Basel, Switzerland: Karger; 1996:28-40.
16. Gottlieb B, Lehvaslaiho H, Beitel LK, Lumbroso R, Pinsky L, Trifiro M. The androgen receptor gene mutations database. Nucleic Acids Res. 1998;26:234-238.
17. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990;173:534-540.
18. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed A, Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat shock protein interaction, and transcription activation. Biochemistry. 1992;31:2393-2399.
19. Culig Z, Stober J, Gast A, et al. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detect Prev. 1996;20:68-75.
20. Culig Z, Hobisch A, Hittmair A, et al. Androgen receptor gene mutations in prostate cancer. Drugs Aging. 1997;10: 50-58.
21. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol. 1993;7:1541-1550.
22. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54:5474-5478.
23. Culig Z, Hobisch A, Hittmair A, et al. Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? Histol Histopathol. 1997;12:781-786.
24. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem. 1996;271:19900-19907.
25. Horoszewicz JS, Leong SS, Ming CT, et al. The LNCaP cell line: a new model for studies on human prostate carcinoma. In: Murphy GD, ed. Models for Prostate Cancer. New York: Alan Liss; 1980:114-132.
26. Schuurmans ALG, Bolt J, Voorhorst M, Blankenstein MA, Mulder E. Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int J Cancer. 1988;42:917-922.
27. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics. 1992;12:241-253.
28. Sleddens HF, Oostra BA, Brinkmann AO, Trapman J. Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet. 1993;2: 493.
29. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-254.
30. Chang CS, Kokontis J, Liao ST. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA. 1988;85:7211-7215.
31. Culig Z, Hobisch A, Cronauer M, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate. 1996;28:329-405.
32. Brass AL, Barnard J, Patai BL, Salvi D, Rukstalis DB. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res. 1995;55:3197-3203.
33. Lewis JG, Lin KY, Kothavale A, et al. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA. 1996;93:3176-3181.
34. Vaughn JP, Iglejart JD, Demirdji S, et al. Antisense DNA downregulation of the ERBB2 oncogene measured by flow cytometric assay. Proc Natl Acad Sci USA. 1995;92:8338-8342.
35. Wagner R. Gene inhibition using antisense oligodeoxynucleotides. Nature. 1994;372:333-335.
36. Flanagan WM, Wagner RW. Potent and selective gene inhibition using antisense oligodeoxynucleotides. Mol Cell Biochem. 1997;172:213-225.
37. Bergan R, Connell Y, Fahmy B, Neckers L. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res. 1993;21:3567-3573.
38. Cook PD. Medicinal chemistry strategies for antisense research. In: Crooke ST, Lebleu B, eds. Antisense Research and Applications. London: CRC Press; 1993:149-187.
39. Yakubov LA, Deeva EA, Zaytova VF, et al. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci USA. 1989;86:6454-6458.
40. Tilley WD, Marcelli M, McPhaul MJ. Expression of the human androgen receptor gene utilizes a common promoter in diverse human tissues and cell lines. J Biol Chem. 1990;265:13776-13781.
41. Trapman J, Ris-Stalpers C, Van der Korput JAGM, et al. The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines. J Steroid Biochem Mol Biol. 1990;37:837-842.
42. Raffo AJ, Perlman H, Chen M-W, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995;55:4438-4445.
43. Gao M, Ossowski L, Ferrari AC. Activation of Rb and decline in androgen receptor precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol. 1999;179:336-346.
44. Furr BJA. The development of Casodex (bicalutamide): preclinical studies. Eur Urol. 1996;29:83-95.
45. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed A, Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry. 1991;31:2393-2399.
46. Knabbe C, Kellner U, Schmahl M, Voight K. Growth factors in human prostate cancer cells: implications for an improved treatment of prostate cancer. J Steroid Biochem Mol Biol. 1991;40:185-192.
47. Schuurmans ALG, Bolt J, Mulder E. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate. 1988;12:55-63.
48. Myers RB, Oelschlager DB, Hockett RD, Rogers MD, Convay-Myers BA, Grizzle WE. The effects of dihydrotestosterone on the expression of p185(erbB-2) and c-erbB-2 mRNA in the prostatic cell line LNCaP. J Steroid Biochem Mol Biol 1996;59:441-447.
49. deFazio A, Chiew Y-E, McEvoy M, Watts CKW, Sutherland R. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells. Cell Growth Differentiation. 1997;8:903-911.
50. Nicholson S, Halcrow P, Sainsbury JR, et al. Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer. 1988;58: 810-814.
51. Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987;1:1398-1402.